. 2021 Aug 30;26(17):5252. doi: 10.3390/molecules26175252

Table 2.

Initial content (mg/100 g weight) and in vitro bioaccessibility of betalains and phenolic compounds in HHP-treated (100 MPa, 350 MPa, 600 MPa; CUT and 5 min) Sanguinos and Pelota prickly pear pulps and in untreated (control) pulps.

		Prickly Pear (Opuntia ficus-indica) Pulps
		Sanguinos		Pelota
	Treatment	Pulp (mg/100 g Weight) ¹	Bioaccessibility (%)	Pulp (mg/100 g Weight) ¹	Bioaccessibility (%)
Indicaxanthin	Control	0.90 ± 0.05^a	53.05 ± 3.01^c	3.92 ± 0.24^c	54.87 ± 2.49^bc
	100 MPa/CUT	0.73 ± 0.05^a	40.93 ± 3.27^b	3.62 ± 0.17^bc	52.81 ± 5.17^bc
	350 MPa/CUT	0.90 ± 0.07^a	44.81 ± 2.24^bc*	5.38 ± 0.05^d	64.83 ± 5.19^c
	600 MPa/CUT	0.72 ± 0.06^a	25.30 ± 2.02^a*	2.85 ± 0.16^ab	36.78 ± 2.94^a
	100 MPa/5 min	0.86 ± 0.07^a	28.84 ± 2.31^a*	3.51 ± 0.14^bc	46.87 ± 3.28^ab
	350 MPa/5 min	0.84 ± 0.06^a	46.98 ± 3.29^bc	3.21 ± 0.08^abc	55.38 ± 2.22^bc
	600 MPa/5 min	0.71 ± 0.01^a	22.33 ± 1.79^a*	2.65 ± 0.50^a	43.12 ± 3.45^ab
Betanin	Control	2.05 ± 0.02^a	42.49 ± 2.69^c	27.91 ± 0.45^ab	44.92 ± 1.52^ab
	100 MPa/CUT	1.80 ± 0.07^a	35.10 ± 2.81^bc	28.44 ± 0.73^ab	48.50 ± 4.74^b
	350 MPa/CUT	2.32 ± 0.23^a	43.01 ± 3.44^c	35.02 ± 0.00^b	50.65 ± 4.05^b
	600 MPa/CUT	2.14 ± 0.22^a	28.67 ± 1.43^ab*	27.93 ± 1.64^ab	39.23 ± 3.14^ab
	100 MPa/5 min	1.98 ± 0.14^a	25.98 ± 1.82^ab*	26.44 ± 1.79^a	35.21 ± 2.46^a
	350 MPa/5 min	2.19 ± 0.23^a	69.57 ± 5.57^d*	25.79 ± 0.27^a	65.88 ± 2.64^c
	600 MPa/5 min	2.02 ± 0.23^a	20.51 ± 1.64^a*	24.79 ± 4.91^a	46.95 ± 3.76^ab
Piscidic acid	Control	58.43 ± 3.53^a	53.61 ± 4.29^ab*	195.63 ± 1.48^a	38.49 ± 3.08^a
	100 MPa/CUT	63.32 ± 7.10^a	56.66 ± 4.53^abc*	255.44 ± 15.40^bc	82.25 ± 6.58^cd
	350 MPa/CUT	71.46 ± 1.26^ab	58.61 ± 3.44^abc	223.96 ± 3.82^ab	62.71 ± 5.02^bc
	600 MPa/CUT	92.66 ± 9.61^b	65.68 ± 5.25^bc	311.03 ± 17.41^d	71.56 ± 3.58^bcd
	100 MPa/5 min	62.78 ± 1.89^a	73.70 ± 1.05^cd*	235.34 ± 15.86^abc	54.39 ± 3.81^ab
	350 MPa/5 min	73.82 ± 8.70^ab	89.36 ± 7.15^d	273.68 ± 2.09^bc	106.20 ± 8.50^e
	600 MPa/5 min	81.97 ± 9.50^ab	42.40 ± 3.39^a*	287.35 ± 29.07^cd	88.43 ± 7.07^de
4-hydrozybenzoic acid glycoside	Control	1.25 ± 0.13^a	20.00 ± 1.60^a	4.47 ± 1.17^a	17.00 ± 1.36^a
	100 MPa/CUT	1.54 ± 0.40^ab	28.53 ± 2.79^b	5.76 ± 0.45^ab	25.89 ± 2.07^b
	350 MPa/CUT	1.87 ± 0.17^abc	27.43 ± 2.19^ab	4.09 ± 0.03^a	21.09 ± 1.24^ab
	600 MPa/CUT	2.48 ± 0.28^c	20.28 ± 1.62^a	9.87 ± 0.47^c	16.76 ± 1.34^a
	100 MPa/5 min	1.60 ± 0.07^ab	22.10 ± 1.55^ab	7.69 ± 0.84^bc	22.81 ± 1.82^ab
	350 MPa/5 min	2.18 ± 0.07^bc	47.13 ± 1.89^c	6.70 ± 0.14^ab	38.44 ± 3.08^c
	600 MPa/5 min	2.19 ± 0.27^bc	19.18 ± 1.53^a*	8.38 ± 1.69^bc	37.48 ± 3.00^c

Results are expressed as mean ± standard deviation (n = 3). Superscript letters indicate statistically significant differences (p ≤ 0.05) between treatments. * Indicates statistically significant differences (p ≤ 0.05) in bioaccessibility between Pelota and Sanguinos varieties. ¹ Data previously reported [11].